Subretinal Photovoltaic Implant AMD Restores Functional Vision in AMD Patients

The Subretinal Photovoltaic Implant AMD delivers the first documented restoration of functional central vision in patients with geographic atrophy secondary to age-related macular degeneration. This device, authorized through Conformité Européenne marking for use in thirty European countries, pairs an implantable array with specialized glasses to convert projected near-infrared light into electrical signals that stimulate remaining retinal tissue. Trial outcomes establish measurable gains in letter recognition and reading ability without compromising residual natural vision.

Multi-Center Evaluation Protocol

Evaluation relied on a prospective multi-center study conducted at seventeen sites across five countries and involving thirty-eight participants with advanced geographic atrophy. The protocol assessed prosthetic visual acuity through standardized Early Treatment Diabetic Retinopathy Study charts and logMAR conversions at the twelve-month mark, while confirming implant placement beneath atrophic macular regions. These design elements directly link the observed letter-score changes to the device’s electrical stimulation mechanism.

Measurable Gains in Letter Recognition

Participants recorded an average gain of 25.5 letters on the acuity chart, exceeding five lines of improvement, with eighty-four percent regaining the capacity to identify letters, numbers, and words. Eighty percent reached a clinically meaningful prosthetic acuity threshold of at least 0.2 logMAR, a result that achieved statistical significance. The absence of any mean reduction in pre-existing natural vision underscores that the intervention augments rather than replaces residual function. The Subretinal Photovoltaic Implant AMD further demonstrated durability of these benefits at the one-year follow-up.

Ad

Strategic Path to Broader Access

European market entry supported by Conformité Européenne certification positions the device for early adoption in health technology assessments that weigh functional vision restoration against the burden of age-related macular degeneration affecting more than five million individuals worldwide. United States regulatory designations as a Breakthrough Device and Humanitarian Use Device may streamline subsequent evidence requirements for coverage determinations. Payers evaluating reimbursement will likely focus on the proportion of patients achieving reading-level vision and the durability of gains demonstrated at one year through the Subretinal Photovoltaic Implant AMD.